Early Feeding for the Prevention of Neonatal Hypoglycaemia: A Systematic Review and Meta-Analysis

Lily F Roberts1, Jane E Harding2, Caroline A Crowther2

  • 1Liggins Institute, University of Auckland, Auckland, New Zealand, lily.roberts@auckland.ac.nz.

Neonatology
|January 9, 2024
PubMed

Insights

Early feeding for newborns may reduce the risk of neonatal hypoglycemia, but current evidence is very uncertain. Despite this, early feeding is recommended due to its numerous other benefits for infant health.

Area of Science:

  • Neonatal care
  • Pediatric nutrition
  • Evidence-based medicine

Background:

  • Neonatal hypoglycemia is a significant concern, often linked to poor feeding.
  • Early feeding is a recommended intervention to prevent hypoglycemia in at-risk newborns.
  • The effectiveness of early feeding for preventing neonatal hypoglycemia requires further clarification.

Purpose of the Study:

  • To systematically review and analyze the evidence on the effectiveness of early feeding in preventing neonatal hypoglycemia.
  • To assess the impact of early feeding on other neonatal outcomes, such as mortality and hospital stay duration.

Main Methods:

  • Comprehensive search of four databases and three clinical trial registries up to May 24, 2023.
  • Inclusion of various study designs including RCTs, quasi-RCTs, and observational studies with comparison groups.
  • Quality assessment using Cochrane Risk of Bias tool or EPHPP, and certainty of evidence using GRADE approach. Meta-analyses were performed using RevMan 5.4.1 or R.

Main Results:

  • Analysis of 19 studies with 175,392 participants, predominantly from low- or lower-middle-income countries.
  • Early feeding may be associated with reduced neonatal hypoglycemia (OR 0.19, 95% CI: 0.10-0.35) and a slightly shorter hospital stay.
  • Evidence regarding early feeding's effect on neonatal mortality is very uncertain, with some studies suggesting a potential reduction (OR 0.51, 95% CI: 0.37-0.72).

Conclusions:

  • Early feeding shows potential in reducing neonatal hypoglycemia incidence, though the supporting evidence is very uncertain.
  • Despite evidence limitations, early feeding is recommended due to its established broader benefits for newborns.
  • Further high-quality research is needed to confirm the definitive impact of early feeding on neonatal outcomes.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
940
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
148
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
175